Although TFR and TKI discontinuation is achievable for CML patients, there is a lack of consistency in TFR treatment policies, and in many cases, treatment discontinuation can lead to eventual disease relapse due to the persistence of CML cells with BCR::ABL1 mutations or LSCs that harbor various BCR::ABL1-independent resistance mechanisms [10,11,12,13,14,15,16,17]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.